In The News

  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms

  • Dr. Richard Stone talks about a patient who benefited from Profile, Dana-Farber's precision medicine program.  Dr. Barrett Rollins and Dr. Matthew Meyerson also comment.

  • Dr. Laurie H. Glimcher is picked as next Chief Executive Officer of Dana-Farber Cancer Institute.

Tags: Appointments

  • Dana-Farber Cancer Institute has appointed Dr. Laurie Glimcher as its new CEO, the first female CEO in the organization’s 69-year history.

Tags: Appointments

  • Dr. Levi Garraway commented on a promising cancer drug that researchers can use in knocking out cancer cells.

Tags: TargetedTherapy

  • Dana-Farber and Lifespan have signed a letter of intent to form a partnership that aims to improve cancer treatment, research and teaching.

Tags: Partnerships

  • Dr. Ann Partridge led a study showing testing for BRCA1 and BRCA2 gene mutations, which significantly increase a woman’s risk of getting breast cancer and ovarian cancer, is on the rise among women ages 40 and under who’ve been diagnosed with breast cancer.

Tags: BreastCancer

  • Dana-Farber is one of 70 top cancer centers nationwide releasing a joint statement encouraging HPV vaccinations.

Tags: CervicalCancer, PatientEducation, GynecologicCancers

  • Dr. Katherine Janeway led a study finding some pediatric cancer patients harbor mutations in their tumor or germline that have potential clinical significance, either for diagnosis or treatment.

Tags: ChildhoodCancer, Genomics, Genetics

  • Dr. George Demetri comments on the call for Medicare and Medicaid to pay for advanced gene-sequencing of tumors.

Tags: PatientEducation, TargetedTherapy, Genetics

  • Dr. Christopher Recklitis commented on patient issues as part of the 2016 cancer survivorship symposium in San Francisco.

Tags: Survivorship

Showing 21-30 of 654 items